News | August 02, 2024
Sun Pharma posts Q1 FY25 consolidated PAT at Rs. 2,835.62 Cr
Sun Pharmaceutical Industries has reported total income of Rs. 13,185.30 crores during the period ended June 30, 2024
Sun Pharmaceutical Industries has reported total income of Rs. 13,185.30 crores during the period ended June 30, 2024
Strong topline growth driven by solid performance across key brands.
Ursodeoxycholic acid or ursodiol is a naturally occurring bile acid that is used dissolve cholesterol gall stones
This product will be manufactured at Lupin’s Nagpur facility in India and will be supplied to low and middle-income countries
More emphasis should be given on investing healthcare resources towards prevention of diseases rather than only focusing on diagnostic and therapeutic options
Ajanta Pharma has reported total income of Rs. 1,171.39 crores during the period ended June 30, 2024
The New Drug Application (NDA) includes data from the Phase III studies OASIS 1, 2 and 3 - showing elinzanetant significantly reduced the frequency and severity of moderate to severe vasomotor symptoms over 12 weeks compared to placebo
Performed an autologous bone marrow transplant, using the patient’s own cells to reduce the chances of infection and rejection
Granules India has reported total income of Rs. 1181.92 crores during the period ended June 30, 2024
The drug will be marketed in different strengths of 150 mg and 440 mg and used in the treatment of patients with HER2
Subscribe To Our Newsletter & Stay Updated
